However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

The same study revealed that 24% of people ... to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

The current review has used an EBM approach to evaluate the strength and validity of the evidence supporting the clinical efficacy and tolerability and the administration benefits of insulin ...

Purpose: The pharmacology, pharmacokinetics, efficacy and tolerability, safety, drug interactions, dosage and administration, cost, and place in therapy of insulin detemir are reviewed.

The calculator estimates the risk ... Americans Will Spend Half Their Lives Taking Prescription Drugs, Study Finds Oct. 12, 2023 — An American born in 2019 will spend a larger share of their ...

New! Sign up for our free email newsletter.

Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time ...

002007.SZ Hualan Biological Engineering Inc.